Dr. Ankur Nandan Varshney

Consultant

14 Years of Experience

Medical Oncologist

MBBS, MD, DM

Reg. No.:69367, Delhi Medical Council

Medanta - The Medicity Hospital, Gurgaon

English

Consultation Fee ₹ 1500

WhatsApp Us

About Dr. Ankur Nandan Varshney

Dr. Ankur Nandan Varshney is an accomplished medical oncologist with an impressive 14 years of experience.
He specializes in areas such as cancer immunotherapy, breast cancer, GI malignancies, lung cancer, urogenital cancers, multiple myeloma, lymphoma, leukemia, pediatric solid tumors, stem cell transplantation, and pain and palliative care.
His educational qualifications include an MBBS from Banaras Hindu University 2010, an MD in General Medicine from Banaras Hindu University 2014, and a DM in Medical Oncology from All India Institute of Medical Sciences (AIIMS), New Delhi, 2021
Dr. Varshney has presented numerous papers at international conferences, showcasing his expertise and dedication to advancing the field of medical oncology.
He is committed to delivering exceptional patient care while actively contributing to the progress of medical oncology.

Book Your Appointment With Dr. Ankur Nandan Varshney

Get a Treatment Plan Within 1 Hour

Name*

Mobile Number*

Query

Education

MBBS, Banaras Hindu University, 2010
MD (General Medicine), Banaras Hindu University, 2014
DM (Medical Oncology), All India Institute of Medical Sciences (AIIMS), New Delhi, 2021

Past Experience

All India Institute of Medical Sciences (AIIMS), New Delhi
Safdarjung Hospital New Delhi
National Cancer Institute Jhajjar Haryana

Awards

Won Deeptanshu Vedanta Gupta Gold Medal
Won “Best Poster Prize and Gold Medal” at UP-APICON 2013
Selected and attended ESMO Lung preceptorship in November 2020
Won ESH scholarship award for the 22nd John Goldman Conference 2020
Won a Young Investigator travel grant for the SOHO Conference 2021.
Selected for Young Investigator Award for SOHO conference 2022

Paper Published

CML-362 Study to Evaluate the Effect of Fatty Meals on Nilotinib Drug Levels in Patients of Chronic Myeloid Leukemia–Chronic Phase and Correlate Its In-Vivo Activity With STAT1, STAT5, and AKT 1 Levels
515P Prognostic significance of elevated serum tumor markers (STM) after the first cycle of chemotherapy in patients with intermediate and poor risk non-seminomatous testicular germ cell tumors (NSGCT)
Prognostic significance of raised serum tumor markers (STM) after two cycles of chemotherapy in men with intermediate- and poor-risk non-seminomatous testicular germ cell tumors (NSGCT) treated at a single-center in India.
Comparison of quality of life (QoL) in survivors of testicular nonseminomatous germ cell tumor (NSGCT) with age-matched controls using EORTC QLQ-C30 questionnaire.
CML-268: Study to Evaluate the Effect of Fatty Meals on Nilotinib Drug Levels in Patients with CML-CP
Poster: CML-268: Study to Evaluate the Effect of Fatty Meals on Nilotinib Drug Levels in Patients with CML-CP
Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient
471PChemotherapy in advanced thymic malignancies
Primary Plasma Cell Leukemia: a retrospective series from a tertiary care center in India
Preemptive plerixafor-based mobilization strategy in multiple myeloma patients for autologous stem cell transplantation
Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient
Preemptive plerixafor-based mobilization strategy in multiple myeloma patients for autologous stem cell transplantation